Oczyesa (Octreotide Subcutaneous Depot)

What Is Oczyesa and What Is It Used For?

Oczyesa is a long-acting injectable form of octreotide, a synthetic analog of the natural hormone somatostatin. It is used for the maintenance treatment of acromegaly in adults whose disease is already controlled with standard octreotide or lanreotide, providing monthly subcutaneous dosing with a pre-filled pen.

Oczyesa contains octreotide, a synthetic octapeptide that mimics the action of natural somatostatin, a hormone that regulates the release of several hormones and growth factors in the body. Conventional octreotide has been available since the late 1980s and is considered a cornerstone of medical therapy for acromegaly and certain neuroendocrine tumors. Oczyesa reformulates this well-established molecule using a lipid-based extended-release technology that enables steady drug release over approximately four weeks after a single subcutaneous injection.

The primary indication for Oczyesa is the maintenance treatment of acromegaly in adult patients who have previously responded to and tolerated treatment with immediate-release octreotide or lanreotide. Acromegaly is a rare but serious hormonal disorder caused by excessive production of growth hormone (GH), almost always due to a benign tumor (adenoma) of the pituitary gland. In acromegaly, elevated GH stimulates the liver to produce large amounts of insulin-like growth factor 1 (IGF-1), which drives many of the clinical features of the disease.

Left untreated, acromegaly causes progressive enlargement of the hands, feet, jaw and facial bones, along with joint pain, excessive sweating, headache, obstructive sleep apnea, cardiomyopathy, diabetes and an increased risk of cardiovascular disease. According to the European Society of Endocrinology and the Pituitary Society, successful treatment aims to normalize GH and IGF-1 levels, shrink the pituitary adenoma, relieve clinical symptoms and reduce long-term mortality to that of the general population.

How Oczyesa Works

Octreotide binds with high affinity to somatostatin receptors (SSTRs), particularly subtypes SSTR2 and SSTR5, which are densely expressed on the growth hormone-producing cells (somatotrophs) of the pituitary gland. Activation of these receptors suppresses GH secretion, leading in turn to a reduction in circulating IGF-1, the hormone responsible for most of the clinical effects of acromegaly. Octreotide is significantly more potent than natural somatostatin at inhibiting GH release and has a much longer duration of action.

In addition to controlling GH and IGF-1 levels, octreotide suppresses secretion of several gastrointestinal and pancreatic hormones, including gastrin, glucagon, insulin, secretin, motilin and pancreatic polypeptide. These broader effects explain many of the gastrointestinal and metabolic side effects associated with the medicine, but also make octreotide valuable in conditions such as functional neuroendocrine tumors and post-pancreatic-surgery complications.

Oczyesa uses a proprietary lipid-based depot technology that transforms from a low-viscosity liquid to a highly structured liquid crystalline matrix when injected under the skin. This matrix gradually releases octreotide into the circulation over approximately 28 days, producing sustained plasma levels adequate to maintain hormone control throughout the dosing interval. This differs from intramuscular octreotide LAR microspheres and subcutaneous lanreotide autogel and is designed to reduce injection volume, simplify administration and improve the subcutaneous delivery experience.

Regulatory Status

Oczyesa was developed to improve the convenience of long-acting octreotide therapy for patients with acromegaly. The product is evaluated by regulatory authorities such as the European Medicines Agency (EMA) as a maintenance treatment for adults with acromegaly. As with other somatostatin analogs, its use is typically initiated and supervised by endocrinologists or specialized pituitary centers, because careful patient selection and biochemical monitoring are essential for optimal outcomes.

What Should You Know Before Taking Oczyesa?

Before starting Oczyesa, your doctor will review your medical history, perform a physical examination, and order blood tests, an ECG, a thyroid ultrasound and a gallbladder ultrasound. You must not use Oczyesa if you are allergic to octreotide or any excipient in the pen. Special caution is needed in gallbladder disease, diabetes, bradycardia or significant liver impairment.

Because octreotide affects multiple hormonal and physiological systems, a thorough pre-treatment assessment is required. The goal is to confirm that Oczyesa is an appropriate choice for your acromegaly, to identify conditions that may need closer monitoring, and to establish baseline values against which future test results can be compared. Patients who have previously tolerated octreotide or lanreotide will generally tolerate Oczyesa, but re-assessment at initiation is still standard practice.

Contraindications

You must not receive Oczyesa if:

• You are allergic (hypersensitive) to octreotide, or to any of the other ingredients in the pre-filled pen
• You have previously experienced a serious hypersensitivity reaction to any somatostatin analog

Always tell your doctor about any previous allergic reactions to medicines before starting Oczyesa, and inform your pharmacist if you have a history of skin or injection-site reactions.

Warnings and Precautions

Talk to your doctor before using Oczyesa if any of the following apply to you:

• Gallbladder disease or gallstones: Octreotide alters the emptying of the gallbladder and bile composition, increasing the risk of gallstones (cholelithiasis) and gallbladder sludge during long-term treatment
• Diabetes or impaired glucose tolerance: Octreotide affects insulin and glucagon secretion and may cause either low blood sugar (hypoglycemia) or high blood sugar (hyperglycemia)
• Heart disease, bradycardia or conduction disorders: Octreotide can slow the heart rate and has been associated with arrhythmias. Dose adjustment of beta-blockers, calcium-channel blockers or fluid/electrolyte management may be needed
• Thyroid disease or goiter: Octreotide can suppress thyroid-stimulating hormone (TSH) secretion and, with long-term use, may cause hypothyroidism
• Liver or kidney impairment: Clearance of octreotide is reduced in patients with hepatic or renal dysfunction, and dose adjustments may be required
• Vitamin B12 deficiency: Long-term octreotide use can lower vitamin B12 levels; monitoring is recommended in at-risk patients
• Severe gastrointestinal symptoms: Pre-existing inflammatory bowel disease or pancreatitis may be aggravated by octreotide

Tests and Monitoring

Before you start Oczyesa, your doctor will typically arrange:

• Blood tests for GH, IGF-1, fasting glucose, HbA1c, liver enzymes, kidney function, TSH, free T4 and vitamin B12
• A resting electrocardiogram (ECG) to assess heart rate and conduction
• An ultrasound of the gallbladder to identify any pre-existing stones or sludge
• A thyroid ultrasound if baseline thyroid function is abnormal or goiter is suspected

During ongoing treatment, regular review is essential. Most guidelines recommend measuring IGF-1 (with or without GH) every 3 to 6 months, blood glucose and HbA1c at least annually (more frequently in patients with diabetes), thyroid function every 6 to 12 months, and gallbladder imaging periodically, especially if symptoms develop. Your endocrinologist will tailor the monitoring schedule to your individual clinical situation.

Pregnancy and Breastfeeding

Experience with octreotide during pregnancy is limited. Animal studies have not shown major teratogenic effects, but human data are insufficient to fully exclude risk. Oczyesa should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. If you are planning pregnancy, discuss the optimal timing and management of acromegaly before conception with your endocrinologist and obstetrician.

• Acromegaly can reduce fertility, and effective treatment sometimes restores it — women of childbearing potential should use reliable contraception during Oczyesa therapy unless pregnancy is actively desired
• If pregnancy occurs during Oczyesa treatment, contact your doctor as soon as possible; treatment is often paused during pregnancy and restarted after delivery
• Octreotide is excreted in small amounts in breast milk; breastfeeding is generally not recommended during active treatment

Driving and Operating Machinery

Oczyesa has little or no influence on the ability to drive and use machines. However, if you experience dizziness, headache, fatigue or hypoglycemia, you should avoid driving or operating heavy equipment until the symptoms have resolved.

Children and Adolescents

The safety and efficacy of Oczyesa in children and adolescents under 18 years of age have not been established. It is not recommended for use in this population.

How Does Oczyesa Interact with Other Drugs?

Oczyesa can interact with insulin and oral antidiabetic drugs (altering glucose control), ciclosporin (reducing its absorption), and beta-blockers or calcium-channel blockers (additive bradycardia). Octreotide also modestly inhibits CYP3A4, which may affect some medicines with a narrow therapeutic index.

Tell your doctor and pharmacist about all medicines you take, including prescription drugs, over-the-counter medicines, vitamins and herbal supplements. Many interactions with octreotide are predictable and manageable with dose adjustments or closer monitoring. The dosing interval of once every four weeks means that Oczyesa exerts continuous pharmacological activity, so co-administered drugs should be considered over the entire month, not only in the days immediately after injection.

Major Interactions

Minor Interactions

Several interactions are minor or of theoretical significance, but worth noting for long-term management:

• Loop diuretics and other drugs that prolong QT interval: Because bradycardia increases QT sensitivity, co-administration warrants ECG monitoring
• Drugs causing electrolyte disturbances: Hypokalemia or hypomagnesemia may potentiate cardiac effects of octreotide and should be corrected
• Vitamin B12 supplements: If long-term octreotide therapy lowers B12, supplementation may be required
• Other somatostatin analogs: Oczyesa should not be combined with other long-acting octreotide or lanreotide products unless specifically directed by an endocrinologist during a transition period

What Is the Correct Dosage of Oczyesa?

Oczyesa is given as a subcutaneous injection of 10 mg or 20 mg once every four weeks, with the dose individualized based on prior octreotide or lanreotide control, GH and IGF-1 levels, symptoms and tolerability. Dose adjustments are typically made every three months based on biochemical response.

The dose of Oczyesa is tailored to each patient by an endocrinologist. Because it is indicated for maintenance therapy of acromegaly, the starting dose is chosen to match the degree of hormone control previously achieved with immediate-release octreotide, octreotide LAR or lanreotide autogel. Biochemical response is then reassessed at regular intervals, and the dose may be titrated up or down within the approved range to maintain IGF-1 within the target range for age and sex, and GH below recommended thresholds.

Adults

Children and Adolescents

Elderly

Renal and Hepatic Impairment

How Oczyesa Is Injected

Missed Dose

If an injection is missed, the patient should contact their healthcare provider as soon as possible. In general, the missed dose is given as soon as the patient and prescriber can arrange it, and the next dose is then scheduled approximately four weeks later to re-establish the regular dosing rhythm. Do not inject two doses close together to make up for a missed dose, as this increases the risk of side effects without providing additional benefit.

Overdose

Accidental overdose with Oczyesa is rare because each pre-filled pen contains a single defined dose. Limited published experience with octreotide overdose indicates symptoms may include severe bradycardia, hypoglycemia or hyperglycemia, abdominal pain and flushing. Treatment is symptomatic and supportive: monitoring of vital signs, ECG, blood glucose and electrolytes, with medical management as needed. If you or someone else has received more Oczyesa than prescribed, contact emergency services or your local poison center for advice.

What Are the Side Effects of Oczyesa?

The most common side effects of Oczyesa reflect the known profile of octreotide and include gastrointestinal symptoms (diarrhea, abdominal pain, flatulence, nausea), gallstones with long-term use, injection-site reactions, headache and fatigue. Less common but important effects include bradycardia, thyroid dysfunction, altered blood glucose, and rare hypersensitivity reactions.

Like all medicines, Oczyesa can cause side effects, although not everyone experiences them. The safety profile is consistent with decades of clinical experience with octreotide. Most adverse effects are mild to moderate and tend to improve with continued treatment, but some — particularly gallbladder and thyroid changes — can develop insidiously and require structured monitoring.

Side Effect Frequency

Gastrointestinal Side Effects

Diarrhea, abdominal discomfort and flatulence are the most frequent adverse effects of octreotide. They usually appear within the first weeks of treatment and often diminish over several months. Practical strategies include smaller, more frequent meals, avoiding very fatty foods, adequate hydration and, if needed, short courses of antidiarrheal medication on the advice of a healthcare professional. Persistent or severe gastrointestinal symptoms should be reported, as they may indicate gallbladder disease, pancreatitis or malabsorption requiring investigation.

Gallbladder Monitoring

Long-term octreotide therapy is associated with an increased risk of gallstones and biliary sludge due to changes in gallbladder motility and bile composition. Most patients remain asymptomatic, but a minority develop acute cholecystitis or biliary pancreatitis, sometimes requiring surgery. Many endocrinology centers perform baseline and periodic gallbladder ultrasound during Oczyesa therapy, for example every 6 to 12 months. New upper abdominal pain, fever or jaundice should always prompt urgent evaluation.

Glucose and Thyroid Changes

Because octreotide suppresses both insulin and glucagon, blood glucose may rise or fall unpredictably. Patients with pre-existing diabetes commonly require adjustments to antidiabetic medication. New-onset diabetes can occasionally develop during long-term treatment. Similarly, TSH suppression and rare autoimmune thyroiditis can produce hypothyroidism, so periodic measurement of TSH and free T4 is advised.

Reporting Side Effects

If you experience any side effects, report them to your doctor, pharmacist or nurse. Reporting suspected adverse reactions through your national pharmacovigilance system (e.g., the EMA's EudraVigilance, the FDA MedWatch program, the UK Yellow Card Scheme) helps improve the safety information available for Oczyesa and for octreotide as a class.

How Should You Store Oczyesa?

Store Oczyesa pre-filled pens in a refrigerator at 2 to 8°C, in the original carton, and away from light. Do not freeze. The pen may be kept at room temperature (below 30°C) for a limited period before use as specified in the product leaflet. Do not use after the expiry date printed on the carton.

Correct storage is essential to preserve the physical properties of the lipid-based depot and the stability of the octreotide molecule. Your pharmacist will dispense Oczyesa ready-to-use, and it should be transported home in an insulated container with cooling elements, especially in warm weather, to maintain refrigeration until it can be placed back into a household refrigerator.

• Refrigerate at 2–8°C: Keep pens in the original carton to protect from light
• Do not freeze: If a pen has been accidentally frozen, it must not be used
• Room temperature window: Once removed, the pen should be allowed to reach room temperature before injection; limited storage outside the refrigerator is permitted as described in the product leaflet — follow the stated duration and temperature
• Single use: Each pen is intended for single use and must not be reused or shared
• Do not use if damaged: Inspect the pen; do not use if it is cracked, leaking, cloudy or contains visible particles that do not clear on gentle mixing as described in the instructions
• Expiry date: Do not use after the expiry date printed on the carton and pen

What Does Oczyesa Contain?

Each Oczyesa pre-filled pen contains octreotide (as octreotide acetate) as the active ingredient, in a lipid-based prolonged-release solution. The formulation uses lipid excipients, a solvent system and water for injections, with no preservatives beyond those required for a single-use product.

The active substance in Oczyesa is octreotide, present as the pharmaceutically acceptable salt octreotide acetate. Octreotide is a synthetic octapeptide that mimics natural somatostatin but with a longer half-life and enhanced selectivity for somatostatin receptor subtypes 2 and 5. Each pen delivers a defined amount of octreotide (for example 10 mg or 20 mg) in a single monthly subcutaneous injection.

Active Ingredient

• Octreotide (as octreotide acetate) — 10 mg or 20 mg per pen depending on strength

Excipients (Inactive Ingredients)

The prolonged-release solution contains lipid-based excipients that together form the in-situ depot after injection. Typical components of this formulation class include:

• Phosphatidylcholine (a phospholipid forming the liquid crystalline matrix)
• Glycerol dioleate or related lipid excipients
• Ethanol (anhydrous) as a co-solvent
• Water for injections

The exact list of excipients and their quantities for a given pen strength is provided in the package leaflet. If you have a known allergy to any of these components, inform your healthcare provider before treatment.

Important Composition Notes

• Alcohol content: The formulation contains a small amount of ethanol. Although the quantity is considered low for clinical safety, patients with a history of alcohol dependence, advanced liver disease, epilepsy or pregnancy should discuss this with their doctor
• No animal-derived ingredients: Octreotide is a synthetic peptide and the excipients are of non-animal origin, which may be relevant for patients with dietary or religious preferences
• Latex-free: Most modern pre-filled pens are manufactured without natural rubber latex — check the product leaflet for confirmation if you have a latex allergy

Appearance and Packaging

Oczyesa is supplied as a slightly viscous, clear to opalescent solution contained within a single-use pre-filled pen. The pen incorporates a fixed needle and a dose-delivery mechanism designed to simplify subcutaneous self-injection. Each carton typically contains one pen together with a package leaflet and detailed instructions for use.